Our clinical research is conducted at St-Priest-en-Jarez, France and clinical testing and quality control in Paris and St. Etienne, France. BioSpeedia is also in the process of relocating part of its overseas production to France.
Our global sales and distribution, product registration in various jurisdictions, liasing with regulatory authorities, logistics and shipping is handled by our distribution arm, BioVitess Ltd. which is located in Belfast, UK.
All business in the United States, including registration, liaising with regulatory authorities, sales and distribution is handled by our subsidiary BioSpeedia LLC. We also have our subsidiary in Switerland, BioSpeedia International.
Forepont provides BioSpeedia access to its global healthcare network, strategic relationships, and access to leading hospitals. Forepont’s Head of Europe, Julien Tizot, is also an Executive Board Member at BioSpeedia.
- Founded in 2011
The establishment of BioSpeedia
After spending 3 decades at Institut Pasteur, Yves Germani and Evelyne Begaud, establish the Company as the official spin-off from the premier French Institute.
Grant from Aide au Partenariat Technologique
Developed fast and accurate lateral flow diagnostic kit to detect Neisseria meningitidis (Menincococcus)
Developed a diagnostic kit to rapidly detect bacterial meningitis using spinal fluid and subsequently using urine samples.
WHO approves MeningoSpeed detection kit in spinal fluid
Received CE Mark for its SARS-CoV-2 rapid antibody test kit
COVID19SEROSpeed-IgM-IgG Test is an immunochromatographic assay designed for the qualitative detection and differentiation of specific IgM and IgG antibodies to coronavirus 2019-nCoV or SARS-CoV-2 in human fingertip blood samples
Seal of Excellence from H2020
For COVID-19 Response
Received CE Mark for its SARS-CoV-2 rapid antigen test kit
COVID-19SPEEDAntigen Test is a colloidal gold enhanced double antibody sandwich immunoassay for qualitative determination of SARS-CoV-2 antigen in human nasal swabs.